Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson’s disease

• Published in: Proceedings of the National Academy of Sciences - PNAS Vol. 112; no. 28; pp. 8756 - 8761
• Main Authors: Kim, Chun-Hyung, Han, Baek-Soo, Moon, Jisook, Kim, Deog-Joong, Shin, Joon, Rajan, Sreekanth, Nguyen, Quoc Toan, Sohn, Mijin, Kim, Won-Gon, Han, Minjoon, Jeong, Inhye, Kim, Kyoung-Shim, Lee, Eun-Hye, Tu, Yupeng, Naffin-Olivos, Jacqueline L., Park, Chang-Hwan, Ringe, Dagmar, Yoon, Ho Sup, Petsko, Gregory A., Kim, Kwang-Soo
• Format: Journal Article
• Language: English
• Published: United States National Academy of Sciences 14.07.2015; National Acad Sciences
• Subjects: Amodiaquine - metabolism; Amodiaquine - pharmacology; Animal behavior; Animals; Behavior, Animal - drug effects; Binding sites; Biological Sciences; Chloroquine - metabolism; Chloroquine - pharmacology; Disease Models, Animal; Dopamine; Gene expression; Ligands; Molecules; Neurogenesis; Neurons; Nuclear Receptor Subfamily 4, Group A, Member 2 - agonists; Nuclear Receptor Subfamily 4, Group A, Member 2 - metabolism; Oxidopamine - toxicity; Parkinson Disease - drug therapy; Parkinson Disease - pathology; Parkinson Disease - psychology; Parkinson's disease; Rats; Rodents; NR4A2; Nurr1; agonist; Parkinson's disease; drug target

Parkinson’s disease (PD), primarily caused by selective degeneration of midbrain dopamine (mDA) neurons, is the most prevalent movement disorder, affecting 1–2% of the global population over the age of 65. Currently available pharmacological treatments are largely symptomatic and lose their efficacy...